$ICU News

Last published 4h ago

4h agoICUSeaStar Medical Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireContinued adoption of the QUELIMMUNE ® therapy yielded 247% increase in net revenue compared to the third quarter of 2025
1w agoICUSeaStar Medical to Report Third Quarter Financial Results on November 11, 2026GlobeNewswireDENVER, Nov. 04, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure
1w agoICUFDA Confirms SeaStar Medical Has Fulfilled the Post-Approval Study Requirements for QUELIMMUNE® for the Treatment of Sepsis-Associated Acute Kidney Injury (AKI) in Pediatric PatientsGlobeNewswireDENVER, Nov. 03, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure
2w agoICUSeaStar Medical Reports Statistically Significant Survival Findings from Post-Approval QUELIMMUNE® SAVE Registry Analysis in Pediatric Sepsis-Associated AKIGlobeNewswireNew late-breaking data presented today at ASN Kidney Week 2026 QUELIMMUNE (SCD-PED) treatment group demonstrates statistically significant higher survival in the primary analysis at Day 60, Day 90, and at hospital
4w agoICUSeaStar Medical Chief Medical Officer Kevin Chung, MD, Named 2026 Recipient of the Combat Nephrology AwardGlobeNewswireAward recognizes Dr. Chung’s extraordinary career as an internationally known expert in burn critical care, combat casualty care, acute organ failure, and extracorporeal organ support Keynote presentation and award
1mo agoICUFDA Grants SeaStar Medical Breakthrough Device Designation for its SCD Therapy for the Treatment of Hyperinflammation in Adult Patients with Sepsis or a Septic ConditionGlobeNewswirePotentially accelerates development, assessment, and review for approval by FDA Sepsis impacts about 1.7 million U.S. adults annually and contributes to nearly one in three in-hospital deaths DENVER, Oct. 07, 2026
2mo agoICUSeaStar Medical to Present at the HC Wainwright 28th Annual Global Investment ConferenceGlobeNewswireDENVER, Sept. 10, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ
3mo agoICUSeaStar Medical Second Quarter 2026 Earnings Call - SEASTAR MEDICAL HOLDING CORPEarnings Call TranscriptsGood day and thank you for standing by. Welcome to the C-STAR Medical Report Second Quarter 2026 Financial Results. At this time, all participants are in a listen-only mode. Please be advised that today's conference is b
3mo agoICUSeaStar Medical Reports Second Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswireAdded 3 top-rated children’s hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing net revenue 82% versus second quarter 2025 Advanced enrollment in the NEUTRALIZE-AKI pivotal
3mo agoICUSeaStar Medical to Report Second Quarter Financial Results on August 12, 2026GlobeNewswireDENVER, Aug. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure
4mo agoICUSeaStar Medical Supports Advances in Critical Care of Pediatric Patients with Acute Kidney Injury (AKI)GlobeNewswireSponsors educational summit of leading pediatric AKI health care experts Announces best practices webinar to further advance new treatment options DENVER, July 14, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical
4mo agoICUSeaStar Medical Announces New ICD-10-PCS Codes for Its SCD Therapy for Acute Kidney InjuryGlobeNewswireEnables standardized inpatient hospital billing for QUELIMMUNE® (SCD-PED) therapy Universal code paves the way for billing of future potential SCD therapies requiring renal replacement therapy DENVER, June 23, 2026
4mo agoICUSeaStar Medical to Present at Upcoming Investor Summit ConferenceGlobeNewswireDENVER, June 22, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure
6mo agoICUSeaStar Medical Reports First Quarter Financial Results and Provides Business UpdatesGlobeNewswireAdded 7 top-rated children's hospitals to QUELIMMUNE® pediatric acute kidney injury (AKI) customer base, increasing first quarter revenue 69% versus first quarter 2025 revenue Advanced enrollment in the
6mo agoICUSeaStar Medical to Report First Quarter Financial Results on May 13, 2026GlobeNewswireDENVER, May 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
7mo agoICUSeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026GlobeNewswireResults from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data In vitro analysis of the SeaStar Medical SCD indicates modulation of
7mo agoICUSeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdatesGlobeNewswireAdded top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollment
8mo agoICUSeaStar Medical to Present at the Life Sciences Investor Forum on March 11thGlobeNewswireDENVER, March 09, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
8mo agoICUSeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKIGlobeNewswireDENVER, March 05, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today that it has completed the required enrollment in the SAVE Registry, a
9mo agoICUSeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)GlobeNewswireStrong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLOBE NEWSWIRE) --
9mo agoICUSeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity ConferenceGlobeNewswireDENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
10mo agoICUSeaStar Medical Announces 2026 MilestonesGlobeNewswireDrive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical's first-in-class SCD therapy for the adult AKI indication – a potential $4.5 billion
10mo agoICUSeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor ConferenceGlobeNewswireDENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
10mo agoICUSeaStar Medical Announces 1-for-10 Reverse SplitGlobeNewswireDENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
11mo agoICUSeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKIGlobeNewswireFDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21 SAVE Surveillance Registry patients Compelling efficacy data to date along with completion
11mo agoICUSeaStar Medical to Present at Upcoming NobleCon21 Investor ConferenceGlobeNewswireDENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
11mo agoICUSeaStar Medical Announces Appointment of Michael Messinger as CFOGlobeNewswireDENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
12mo agoICUSeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireBusiness highlights include: Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI)Commercial use of QUELIMMUNE therapy demonstrates positive survival
1y agoICUSeaStar Medical to Report Third Quarter Financial Results on November 13, 2025GlobeNewswireDENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
1y agoICUSeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in ChildrenGlobeNewswireData show results consistent with clinical trial experienceA high level of safety – no device-related adverse eventsStrong survival data extending to 90 days
1y agoICUSeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney InjuryGlobeNewswireIndependent DSMB reports zero device-related safety issuesSupports potential clinical benefitTrial sample size re-estimated to strengthen statistical power DENVER, Sept. 24, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical
1y agoICUSeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in ChildrenGlobeNewswireDENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today that preliminary results from the SAVE Surveillance Registry will be
1y agoICUSeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment ConferenceGlobeNewswireDENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
1y agoICUSeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased SurvivalGlobeNewswireDENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
1y agoICUSeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireBusiness highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolledThree new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury
1y agoICUSeaStar Medical to Report Second Quarter Financial Results on August 13, 2025GlobeNewswireDENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
1y agoICUSeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)GlobeNewswireTrial now over 60% enrolled with 125 of 200 anticipated patients Recent new site activation brings total clinical trial sites to 16 Interim analysis of first 100 patients remains on track for 3Q 2025 DENVER, Aug. 06,
1y agoICUSeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireDENVER, July 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
1y agoICUSeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry PatientsGlobeNewswireDENVER, July 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company, announced today positive preliminary results from the SAVE Surveillance Registry which
1y agoICUSeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance RegistryGlobeNewswireHighest Rated Children's Medical Centers Now Employ QUELIMMUNE for Ultra-Rare Cases of Pediatric AKI HDE Surveillance Registry Data Captures Key Metrics for Future Analysis of QUELIMMUNE Performance DENVER, July 16,
1y agoICUSeaStar Medical Announces $4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireDENVER, July 10, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
1y agoICUSeaStar Medical Expands QUELIMMUNE Adoption for Critically Ill Pediatric Patients with Acute Kidney Injury (AKI)GlobeNewswireDENVER, July 08, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
1y agoICUSeaStar Medical Announces Positive Nasdaq Listing DeterminationGlobeNewswireDENVER, July 02, 2025 (GLOBE NEWSWIRE) -- Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
1y agoICUSeaStar Medical Reports Update on Nasdaq Listing StatusGlobeNewswireDENVER, June 25, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU) a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and
1y agoICUSeaStar Medical Announces Two Feature Stories on QUELIMMUNE Adoption and Patient Testimonial of Life-Saving TherapyGlobeNewswireCincinnati Children's Hospital Medical Center Discusses QUELIMMUNE Therapy Adoption A Father and Patient Describe Their Real-Life Experience with the QUELIMMUNE Therapy DENVER, June 24, 2025 (GLOBE NEWSWIRE) --
1y agoICUSeaStar Medical Announces Pricing of Up to $8 Million Public OfferingGlobeNewswireDENVER, June 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (the "Company" or "SeaStar Medical") (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically
1y agoICUAREVA Institute and SeaStar Medical Announce DoD Award of Prestigious Military Grant to AREVA Institute to Evaluate SeaStar Medical's SCD Therapy to Advance Breakthrough Burn and Sepsis ResearchGlobeNewswireSAN ANTONIO, Texas and DENVER, Colorado, June 11, 2025 (GLOBE NEWSWIRE) -- The Autonomous Reanimation and Evacuation (AREVA) Research Institute and SeaStar Medical (NASDAQ:ICU) announced today that a new United States
1y agoICUSeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD TherapyGlobeNewswireCoverage marks SeaStar Medical's second award by CMS for reimbursement of medical expenses for Medicare and Medicaid patients in a clinical trial Stands out as rare award with less than 100 clinical trials covered
1y agoICUSeaStar Medical Reports First Quarter 2025 Financial Results and Provides Business UpdatesGlobeNewswireQUELIMMUNE adoption drives four-fold increase in sequential quarter net revenue NEUTRALIZE AKI trial exceeds 50% enrollment, triggers start of Interim AnalysisWebcast Today at 4:30 pm Eastern Time DENVER, May 14, 2025
1y agoICUSeaStar Medical Reaches Interim Enrollment Target for NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney InjuryGlobeNewswireDENVER, May 13, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (NASDAQ:ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and